Sophie Lebail
2023-03-13
Disease
PCG Registry
Abatary Discription
The primary objective of the project is to describe the demographic characteristics, cancer type (tumour histology), treatment modalities and objectives (curative or palliative intent), and safety data of patients with breast cancer treated by the IBA proton therapy system.
The primary endpoint is to assess the safety of proton therapy delivery by the IBA proton therapy system.
This assessment will supplement the PMCF report, describing the acute and late Adverse Events (AE), Serious AE (SAE), and will be used to confirm the acceptability of the risk/benefit ratio of the IBA proton therapy system.